Entropy Technologies LP Buys New Shares in Tempus AI, Inc. $TEM

Entropy Technologies LP purchased a new position in shares of Tempus AI, Inc. (NASDAQ:TEM) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 29,165 shares of the company’s stock, valued at approximately $1,853,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. ARK Investment Management LLC raised its position in shares of Tempus AI by 35.9% in the first quarter. ARK Investment Management LLC now owns 7,501,399 shares of the company’s stock valued at $361,867,000 after purchasing an additional 1,981,755 shares during the period. Vanguard Group Inc. raised its position in shares of Tempus AI by 6,247.5% in the first quarter. Vanguard Group Inc. now owns 5,995,117 shares of the company’s stock valued at $289,204,000 after buying an additional 5,900,668 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its holdings in Tempus AI by 109.9% in the 1st quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 50,666 shares of the company’s stock valued at $2,444,000 after acquiring an additional 26,533 shares in the last quarter. Jump Financial LLC acquired a new position in Tempus AI in the first quarter valued at about $8,545,000. Finally, Tyler Stone Wealth Management acquired a new position in shares of Tempus AI in the 1st quarter valued at approximately $386,000. 24.22% of the stock is owned by institutional investors.

Tempus AI Price Performance

Shares of NASDAQ:TEM opened at $70.29 on Friday. Tempus AI, Inc. has a 1-year low of $31.36 and a 1-year high of $104.32. The stock has a market cap of $12.51 billion, a PE ratio of -59.07 and a beta of 4.86. The stock’s fifty day simple moving average is $83.63 and its two-hundred day simple moving average is $71.98. The company has a current ratio of 3.28, a quick ratio of 3.12 and a debt-to-equity ratio of 2.45.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. Tempus AI had a negative net margin of 18.45% and a negative return on equity of 73.21%. The business had revenue of $334.21 million during the quarter, compared to the consensus estimate of $328.89 million. During the same period in the prior year, the firm posted ($0.46) EPS. The firm’s quarterly revenue was up 84.7% compared to the same quarter last year. Tempus AI has set its FY 2025 guidance at EPS. As a group, analysts forecast that Tempus AI, Inc. will post -6.15 EPS for the current fiscal year.

Insider Activity

In related news, EVP Erik Phelps sold 3,533 shares of the firm’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $65.54, for a total transaction of $231,552.82. Following the completion of the sale, the executive vice president owned 90,582 shares in the company, valued at approximately $5,936,744.28. This trade represents a 3.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Eric P. Lefkofsky sold 166,250 shares of Tempus AI stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $68.97, for a total transaction of $11,466,262.50. Following the completion of the sale, the chief executive officer directly owned 9,041,283 shares in the company, valued at approximately $623,577,288.51. This represents a 1.81% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 1,225,264 shares of company stock worth $95,497,911. 26.27% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms have recently commented on TEM. Weiss Ratings reissued a “sell (d-)” rating on shares of Tempus AI in a report on Wednesday, October 8th. HC Wainwright dropped their price target on shares of Tempus AI from $98.00 to $89.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Cowen lowered Tempus AI from a “buy” rating to a “hold” rating in a research note on Tuesday, October 21st. Piper Sandler dropped their target price on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating on the stock in a report on Tuesday, November 11th. Finally, BTIG Research reissued a “buy” rating and issued a $96.00 price target on shares of Tempus AI in a research note on Wednesday, November 5th. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Tempus AI presently has an average rating of “Hold” and a consensus target price of $80.00.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.